ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
PainReform Ltd

PainReform Ltd (PRFX)

0.488
-0.012
(-2.40%)
Closed July 12 4:00PM
0.488
0.00
( 0.00% )
Pre Market: 4:00AM

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
0.488
Bid
0.485
Ask
0.5061
Volume
-
0.00 Day's Range 0.00
0.432 52 Week Range 11.5499
Market Cap
Previous Close
0.488
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
146,509
Shares Outstanding
1,728,347
Dividend Yield
-
PE Ratio
-0.09
Earnings Per Share (EPS)
-5.41
Revenue
-
Net Profit
-9.34M

About PainReform Ltd

PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics.

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Herzliya, Center, Isr
Founded
1970
PainReform Ltd is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker PRFX. The last closing price for PainReform was $0.49. Over the last year, PainReform shares have traded in a share price range of $ 0.432 to $ 11.5499.

PainReform currently has 1,728,347 shares outstanding. The market capitalization of PainReform is $843,433.34 . PainReform has a price to earnings ratio (PE ratio) of -0.09.

PRFX Latest News

PainReform Completes Enrollment in the Second Part of its Phase 3 Bunionectomy Trial for PRF-110

TEL AVIV, Israel, June 26, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation...

PainReform Announces Receipt of Nasdaq Minimum Bid Price Notification

TEL AVIV, Israel, May 31, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation...

PainReform Provides Business Update for the First Quarter of 2024

Reaches 50% enrollment in the second part of its Phase 3 clinical trial of PRF-110 in bunionectomy Remains on track to announce top-line data in Q3 2024 TEL AVIV, Israel, May 15, 2024 (GLOBE...

PainReform CEO Ilan Hadar Discusses Latest Developments Related to PRF-110 and its Potential to Help Tackle the Opioid Epidemic on Proactiveinvestors.com

TEL AVIV, Israel, May 08, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation...

PainReform Announces Closing of $4 Million Public Offering

TEL AVIV, Israel, April 18, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical-stage specialty pharmaceutical company focused on the...

PainReform Announces Pricing of $4 Million Public Offering

TEL AVIV, Israel, April 16, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical-stage specialty pharmaceutical company focused on the...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.03427.536359629790.45380.520.4538674120.48905219CS
4-0.0164-3.251387787470.50440.640.4321635280.47526045CS
12-0.384-44.03669724770.8720.96960.4321465090.63990309CS
26-1.982-80.24291497982.472.630.4321380111.07532886CS
52-9.672-95.196850393710.1611.54990.4322062756.16701947CS
156-27.612-98.263345195728.178.40.43236241020.20792587CS
260-66.212-99.268365817166.778.40.43232205223.39488313CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
DJTTrump Media and Technology Group Corporation
$ 50.38
(63.09%)
4.07M
CGBSCrown LNG Holdings Ltd
$ 5.23
(52.48%)
2.74M
PHUNPhunware Inc
$ 8.68
(48.89%)
1.11M
DATSDatChat Inc
$ 1.42
(36.54%)
1.68M
CPOPPop Culture Group Company Ltd
$ 1.60
(24.03%)
660.16k
GPAKGamer Pakistan Inc
$ 0.1384
(-25.67%)
458
QLGNQualigen Therapeutics Inc
$ 0.3451
(-20.50%)
1.01M
QNCXQuince Therapeutics Inc
$ 0.622
(-20.07%)
13
VEVVicinity Motor Corporation
$ 0.594
(-16.70%)
341.08k
LTRYLottery com Inc
$ 1.10
(-16.03%)
1.54k
MAXNMaxeon Solar Technologies Ltd
$ 0.2275
(-4.21%)
4.72M
DJTTrump Media and Technology Group Corporation
$ 50.38
(63.09%)
4.07M
CGBSCrown LNG Holdings Ltd
$ 5.23
(52.48%)
2.74M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
$ 15.34
(9.42%)
1.75M
AREBAmerican Rebel Holdings Inc
$ 0.6085
(17.02%)
1.71M

PRFX Discussion

View Posts
Sirpeter Sirpeter 2 weeks ago
... heading for the promised land...just starting
👍️0
Sirpeter Sirpeter 2 weeks ago
...all I know is this is way oversold and the product seems to be working...to be honest Im here for a quick trade...I make the big money playing options
👍️0
Tool_power Tool_power 2 weeks ago
We should get a bump, especially if the promising results in April are confirmed (96 hr pain relief Vs. 72 hr, and better performance than the leading competitor product).

But Hadar was saying that after these clinical trials for Bunionectomy (hard tissue) were concluded that they would then do the Hernia operation (soft tissue) clinical trials in 2025 with planned NDA submission in 2026. I wonder if that strategy will change now?
👍️0
Sirpeter Sirpeter 2 weeks ago
Dont know...doesnt matter as long as the last phase of the drug trial is happening...we should get a bump soon
👍️0
Tool_power Tool_power 2 weeks ago
Interesting that CEO Hadar stepped down. I have no problem with this as I didn’t think he was very good, but I wonder why he made this decision.

I have more confidence in Dr. Ehud Geller as the interim.
👍️0
Sirpeter Sirpeter 2 weeks ago
Added some today...low enough...dont see any danger of RS...will be past $1 soon enough
👍️0
Monksdream Monksdream 1 month ago
PRFX new 52 week low
👍️0
Sirpeter Sirpeter 1 month ago
Think we have to wait for more news on this one...need to know whwn drug trial ends...maybe around Sept
👍️0
Tiger Money Tiger Money 1 month ago
Taking off a little bit now
👍️0
Monksdream Monksdream 1 month ago
PRFX new 52 week low
👍️0
Tiger Money Tiger Money 1 month ago
Nice, thank you
👍️0
Sirpeter Sirpeter 1 month ago
That could hapoen but theres still plenty of time on the clock...I sold this a while ago and looking to buy back in a few mos...this will be a good one when it runs
👍️0
Tiger Money Tiger Money 1 month ago
These guys have to do a reverse to get back in compliance? Thanks
👍️0
Sirpeter Sirpeter 3 months ago
Added...low enough
👍️0
Monksdream Monksdream 3 months ago
PRFX new 52 lo
👍️0
Tool_power Tool_power 3 months ago
Bunionectomy is just one of several applications for this 1st product. The market is actually quite substantial. They are targeting at least 10-12 countries. I’ll be buying more around $0.40.
👍️0
Monksdream Monksdream 3 months ago
More new lows to come this afternoon when I return from the supermarket
👍️ 1
BooDog BooDog 3 months ago
Bonionectomy??? Isreal.... $4M @ .80????


wow. Not even looking any further on this one.

Surprised this isn't on the otc...


yet

I was stalking your "new 52 week lows"
👍️0
Monksdream Monksdream 3 months ago
PRFX new 52 lo
👍️0
Monksdream Monksdream 3 months ago
PRFX new 52 lo
👍️0
Tool_power Tool_power 3 months ago
PRFX: Looks like company raising funds now through selling of shares, which I don’t mind because they have a good business plan and they’re executing against it.

Buckle up, it’s gonna be a roller coaster ride!
👍️0
Monksdream Monksdream 3 months ago
PRFX new 52 lo
👍️0
Awl416 Awl416 3 months ago
What leaked?
👍️0
Monksdream Monksdream 3 months ago
PRFX over $3
👍️0
Sirpeter Sirpeter 3 months ago
I'm wrong, only the first half of part 3 are complete...an earlier PR didn't tell us they were doing it this way...seems now the drug trial won't end until about Sept...oh well
👍️0
Sirpeter Sirpeter 3 months ago
Drug trial should be nearly complete
...will help us
👍️0
Monksdream Monksdream 4 months ago
PRFX under $2
👍️0
Monksdream Monksdream 4 months ago
PRFX 10Q due March 14
👍️0
Sirpeter Sirpeter 7 months ago
Come on back to PRFX...it needs you...up, up and away it's going
👍️0
Sirpeter Sirpeter 7 months ago
PRFX is on the march...up 1,2,3,4....up 1,2,3,4
👍️0
Sirpeter Sirpeter 7 months ago
Waking up for those who listen...( Actually I feel I'm talking to myself, if so, I will be the one making all d- money lol)
👍️0
Sirpeter Sirpeter 9 months ago
Way oversold here...a big pop is coming soon
👍️0
Sirpeter Sirpeter 9 months ago
GL
👍️0
surfer44 surfer44 9 months ago
Yeah, I like the story. Right now I'm going with "what is" and not "what if".
👍️0
Sirpeter Sirpeter 9 months ago
PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced plans to commence the second part of the Company’s phase 3 trial to evaluate PRF-110 in patients undergoing bunionectomy surgery.

Starting the second part of the bunionectomy Phase III study follows the clearance by FDA of the DMF (Drug Master File) held by the Company’s API manufacturer. This second part of the trial is expected to proceed in the next quarter of 2023.

As announced earlier this year, the company completed the first part of its Phase 3 clinical trial of PRF-110, in which 15 patients undergoing bunionectomy surgery were enrolled at two clinical sites in Texas. The Company reported positive safety data in the first part of the Phase 3 clinical trial with no serious adverse events (SAEs) reported, suggesting a substantial potential advantage to using PRF-110 over opioids. As previously reported, PRF-110 provided pain reduction for up to 72 hours post-operatively in the Company’s prior Phase 2 proof-of-concept clinical study in herniorrhaphy (hernia repair).

The upcoming second part of the trial will be a double-blind study, in which the Company plans to randomize approximately 400 patients at seven clinical sites in the U.S.

PRF-110 is a highly uniform solution, resulting in consistent sustained and extended release of the analgesic. Ropivacaine, the active drug used in PRF-110, is a safe, well-tolerated, and well-characterized local anesthetic. The other components that comprise the remainder of the PRF-110 formulation have been designated by the FDA as Generally Recognized as Safe (GRAS), mitigating many potential safety issues common in drug development.

Key surgical benefits observed to date include:

PRF-110 does not alter the integrity of standard surgical devices, such as sutures and meshes used in a large variety of surgical procedures

PRF-110 does not interfere with normal macro and microscopic wound healing of surgical incisions in soft tissue and bone models

PRF-110 does not alter the tensile strength of healed skin at the surgical sites in an animal study mimicking surgical procedures

Ilan Hadar, Chief Executive Officer of PainReform, stated, “We expect to commence the second part of our phase 3 clinical study in Q4, 2023 following positive pharmacokinetic (PK) data in the first part of our Phase 3 clinical trial of PRF-110 in bunionectomy, which exceeded the FDA safety requirements.   This data reinforces the favorable results of our prior Phase 2 data in hernia repair, which provides us confidence in the outlook for PRF-110. Although we encountered delays due to issues experienced by the manufacturer of our API (active pharmaceutical ingredient), unrelated to PFR-110, we worked closely with them to rapidly resolve these matters, and our clinical program is now back on track. following a positive completion of the DMF review by the FDA. We look forward to advancing the trial, which we expect to complete and report the results by mid-2024. Importantly, we believe PRF-110 has the potential to address a significant unmet need in the multi-billion postoperative pain market with the potential to become standard of care as an alternative to systemic opioids.”

About PainReform

PainReform is a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics. PRF-110, the Company's lead product is based on the local anesthetic ropivacaine, targeting the postoperative pain relief market. PRF-110 is an oil-based, viscous, clear solution deposited directly into the surgical wound bed before closure to provide localized and extended postoperative analgesia. The Company's proprietary extended-release drug-delivery system is designed to provide an extended period of post-surgical pain relief without the need for repeated dose administration while reducing the potential need for the use of opiates. For more information, please visit www.painreform.com.

👍️0
surfer44 surfer44 9 months ago
I sold. Too speculative. And I need the money elsewhere. GL
👍️0
Sirpeter Sirpeter 9 months ago
Starting to accumulate more...oversold
👍️0
Monksdream Monksdream 10 months ago
PRFX new 52 week low
👍️0
surfer44 surfer44 10 months ago
Just opened a small position. Interesting stock. Venture capital only...
👍️0
Sirpeter Sirpeter 10 months ago
You said it buddy...it won't be for long
👍️0
Golden Cross Golden Cross 11 months ago
Good deal
👍️0
Sirpeter Sirpeter 11 months ago
Added more today
👍️0
TheGreenReaper TheGreenReaper 11 months ago
Waiting on reversal.
👍️0
Golden Cross Golden Cross 11 months ago
Looks bottomed
👍️0
Sirpeter Sirpeter 11 months ago
Could be $100+ after phase 3 drug trial ends...soon
👍️0
Sirpeter Sirpeter 11 months ago
It's a good day to add PRFX to your portfolio...it's dirt cheap

Enjoy yur day
👍️0
dinogreeves dinogreeves 11 months ago
PRFX is undervalued, this price shouldn't be where it is now.
👍️0
BEIJING BILL BEIJING BILL 11 months ago
good dey sir
👍️0
Sirpeter Sirpeter 11 months ago
I add a little almost daily...very confident we're close
👍️0
TheGreenReaper TheGreenReaper 11 months ago
Thought it was but not yet
👍️0

Your Recent History

Delayed Upgrade Clock